5-Amino-1MQ
5-Amino-1-Methylquinolinium
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates cellular energy metabolism and is upregulated in white adipose tissue of obese individuals. By blocking NNMT, it increases intracellular NAD+ and SAM (S-adenosyl methionine) concentrations, shifting fat cells from storage toward energy expenditure. It is primarily researched as an oral metabolic modulator for obesity, metabolic syndrome, and cellular energy optimization.
作用機序
Small molecule inhibitor of NNMT. Increases cellular NAD+ and SAM levels, activating SIRT1-dependent energy expenditure pathways.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Research protocols use 50-150mg orally once daily. Often taken with food.
研究ノート
Clinical Research Status
5-Amino-1MQ is in preclinical development with published in vitro and animal model data but has not yet entered formal human clinical trials. Research is primarily based on studies from the University of Texas Health Science Center demonstrating its effects on adipocyte differentiation and metabolic pathways. The compound is available through research chemical suppliers and compounding pharmacies, though it lacks regulatory approval for any therapeutic indication.
Key Published Findings
Studies in diet-induced obesity mouse models showed that 5-Amino-1MQ treatment reduced body weight by approximately 7% over 11 days without affecting food intake or causing lean mass loss. In vitro research demonstrated that NNMT inhibition with 5-Amino-1MQ reduced lipid accumulation in differentiating adipocytes and increased intracellular NAD+ levels by 2-fold. The compound has been shown to shrink existing fat cells, prevent new fat cell maturation, and increase the activity of sirtuin-dependent metabolic pathways through NAD+ elevation.
Safety Profile
Preclinical toxicity data suggests 5-Amino-1MQ is well-tolerated in animal models at effective doses without significant organ toxicity or behavioral changes. As a relatively new research compound without human trial data, the long-term safety profile in humans remains uncharacterized. Users in the research community have self-reported generally mild side effects at doses of 50-150mg daily, though systematic adverse event data is absent.
Drug Interactions & Contraindications
Theoretical interactions exist with other compounds that affect methyl donor metabolism, including SAM-e supplements and medications metabolized by methyltransferase enzymes. Given its mechanism of increasing intracellular NAD+, concurrent use with NAD+ precursors (NMN, NR) may produce additive effects that are not yet characterized for safety. Individuals with hormone-sensitive conditions should exercise caution, as NNMT plays roles in estrogen and catecholamine metabolism.
Comparison to Related Compounds
Unlike traditional fat loss compounds that work through appetite suppression or thermogenesis (DNP, clenbuterol), 5-Amino-1MQ targets the metabolic programming of fat cells themselves through epigenetic regulation. Other NNMT inhibitors exist in research (methylquinolinium analogs), but 5-Amino-1MQ is the most characterized and commercially available for research purposes. Its mechanism of simultaneously increasing NAD+ and SAM makes it mechanistically distinct from direct NAD+ precursors like NMN, which do not address NNMT-mediated metabolic dysregulation.
Community Observations
Users typically report subtle but measurable changes in body composition over 4-8 weeks at oral doses of 50-150mg daily, with fat loss concentrated in visceral and stubborn subcutaneous depots. The compound is frequently stacked with other metabolic agents and exercise programs, making isolated effects difficult to assess in anecdotal reports. The research community notes that 5-Amino-1MQ appears to work best as a recomposition agent rather than a dramatic weight loss compound, and effects seem more pronounced in individuals with higher baseline body fat percentages.
半減期
~2-3 hours (oral)
再構成
N/A (oral capsule form)
保存
乾燥粉末
Room temperature. Protect from moisture and light.
再溶解
N/A (oral form)
米国法的状況
また知られる名前
よくある質問
5-Amino-1MQとは何ですか?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates cellular energy metabolism and is upregulated in white adipose tissue of obese individuals. By blocking NNMT, it increases intracellular NAD+ and SAM (S-adenosyl methionine) concentrations, shifting fat cells from storage toward energy expenditure. It is primarily researched as an oral metabolic modulator for obesity, metabolic syndrome, and cellular energy optimization.
5-Amino-1MQはどのように作用しますか?
Small molecule inhibitor of NNMT. Increases cellular NAD+ and SAM levels, activating SIRT1-dependent energy expenditure pathways.
5-Amino-1MQの米国での規制状況は?
Research chemical (not FDA-approved)
5-Amino-1MQの半減期は?
~2-3 hours (oral)
5-Amino-1MQの別名は?
5-Amino-1-Methylquinolinium
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む